
    
      De-intensified radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes
      and 54 Gy to subclinical regions at risk in 30 fractions. Omission of level IB lymph node
      regions from the elective nodal volumes.

      Chemotherapy will be administered as per standard of care, consisting of concurrent cisplatin
      (high-dose: 100mg/m2 IV every 3 weeks or low-dose: 40mg/m2 IV every week) or cetuximab (at
      the discretion of medical oncologist).
    
  